Skip to main content
Top

Open Access 15-04-2024 | Original Research

Interchanging Reusable and Disposable Nebulizers Used with Home-Based Compressors May Result in Inconsistent Dosing: A Laboratory Investigation with Device Combinations Supplied to the US Healthcare Environment

Authors: Judy Schloss, Dominic P. Coppolo, Jason A. Suggett, Mark W. Nagel, Jolyon P. Mitchell

Published in: Pulmonary Therapy

Login to get access

Abstract

Introduction

Reusable nebulizer–compressor combinations deliver inhaled medications for patients with chronic lung diseases. On hospital discharge, the patient may take home the disposable nebulizer that was packaged and combine it with their home compressor. Though this practice may reduce waste, it can increase variability in medication delivery. Our study compared several reusable and disposable nebulizers packaged with compressor kits used in the US. We included a common disposable hospital nebulizer that may not be supplied with popular home kits but may be brought home after a hospitalization or emergency department visit. We focused on fine droplet mass < 4.7 μm aerodynamic diameter (FDM<4.7 μm), associated with medication delivery to the airways of the lungs.

Methods

We evaluated the following nebulizer–compressor combinations (n = 5 replicates):
1.
OMBRA® Table Top Compressor with MC 300® reusable and Airlife™ MistyMax™ 10® disposable nebulizer,
 
2.
Sami-the-Seal® compressor with SideStream® reusable and disposable nebulizers and Airlife™ MistyMax 10™ disposable nebulizer,
 
3.
VIOS® compressor with LC Sprint® reusable, and VixOne® and Airlife™ MistyMax™ disposable nebulizers,
 
4.
Innospire® Elegance® compressor with SideStream® reusable and disposable nebulizers and Airlife™ MistyMax 10™ disposable nebulizer,
 
5.
Willis-the-Whale® compressor with SideStream® reusable and disposable nebulizers and Airlife™ MistyMax 10™ disposable nebulizer,
 
6.
Pari PRONEB® Max compressor with LC Sprint® reusable and Airlife™ MistyMax 10™ disposable nebulizer.
 
We placed a 3-ml albuterol solution (0.833 mg/ml) in each nebulizer. A bacterial/viral filter was attached to the nebulizer mouthpiece to capture emitted medication, with the filter exit coupled to a simulator of a tidal breathing adult (rate = 10 cycles/min; Vt = 600 ml; I/E ratio = 1:2). The filter was replaced at 1-min intervals until onset of sputter. Droplet size distributions (n = 5 replicates/system) were determined in parallel by laser diffractometry.

Results

Cumulative FDM<4.7 μm varied from 381 ± 33 μg for the best performing combination (Proneb/LC-Sprint) to 150 ± 21 μg for the system with the lowest output (VIOS®/MistyMax 10™).

Conclusions

Substituting one nebulizer for another can result in large differences in medication delivery to the lungs.
Literature
1.
go back to reference Collins N. Nebulizer therapy in cystic fibrosis: an overview. J R Soc Med. 2009;102:S11–7.CrossRef Collins N. Nebulizer therapy in cystic fibrosis: an overview. J R Soc Med. 2009;102:S11–7.CrossRef
2.
go back to reference Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD: J Chron Obstr Dis. 2011;9(1):58–72.CrossRef Dhand R, Dolovich M, Chipps B, Myers TR, Restrepo R, Farrar JR. The role of nebulized therapy in the management of COPD: evidence and recommendations. COPD: J Chron Obstr Dis. 2011;9(1):58–72.CrossRef
4.
go back to reference Awad SM, Berlinski A. Crossover evaluation of compressors and nebulizers typically used by cystic fibrosis patients. Respir Care. 2018;63(3):294–300.CrossRefPubMed Awad SM, Berlinski A. Crossover evaluation of compressors and nebulizers typically used by cystic fibrosis patients. Respir Care. 2018;63(3):294–300.CrossRefPubMed
5.
go back to reference Lester M, Eidson D, Blair S, et al. Cystic Fibrosis Foundation nebulizer and compressor survey. Respir Care. 2021;66(12):1840–7.CrossRefPubMed Lester M, Eidson D, Blair S, et al. Cystic Fibrosis Foundation nebulizer and compressor survey. Respir Care. 2021;66(12):1840–7.CrossRefPubMed
6.
go back to reference Smith EC, Denyer J, Kendrick AH. Comparison of twenty-three nebulizer/compressor combinations for domiciliary use. Eur Respir J. 1995;8:1214–21.CrossRefPubMed Smith EC, Denyer J, Kendrick AH. Comparison of twenty-three nebulizer/compressor combinations for domiciliary use. Eur Respir J. 1995;8:1214–21.CrossRefPubMed
7.
go back to reference Reisner C, Katial RK, Bartelson BB, Buchmeir A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol. 2002;86(5):566–74.CrossRef Reisner C, Katial RK, Bartelson BB, Buchmeir A, Rosenwasser LJ, Nelson HS. Characterization of aerosol output from various nebulizer/compressor combinations. Ann Allergy Asthma Immunol. 2002;86(5):566–74.CrossRef
8.
go back to reference Heyder J, Bebhard J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005–15 um. J Aerosol Sci. 1986;17:811–25.CrossRef Heyder J, Bebhard J, Rudolf G, Schiller CF, Stahlhofen W. Deposition of particles in the human respiratory tract in the size range 0.005–15 um. J Aerosol Sci. 1986;17:811–25.CrossRef
9.
go back to reference Finlay WH, Stapleton WH, Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J Aerosol Sci. 1997;28(7):1301–9.CrossRef Finlay WH, Stapleton WH, Zuberbuhler P. Fine particle fraction as a measure of mass depositing in the lung during inhalation of nearly isotonic nebulized aerosols. J Aerosol Sci. 1997;28(7):1301–9.CrossRef
10.
go back to reference Everard ML, Devadason SG, Summers QA, Le Souef PN. Factors affecting total and “respirable” dose delivered by a salbutamol metered dose inhaler. Thorax. 1995;50(7):746–9.CrossRefPubMedPubMedCentral Everard ML, Devadason SG, Summers QA, Le Souef PN. Factors affecting total and “respirable” dose delivered by a salbutamol metered dose inhaler. Thorax. 1995;50(7):746–9.CrossRefPubMedPubMedCentral
11.
go back to reference Tashkin DP. A review of nebulized drug delivery in COPD. Int J COPD. 2016;11:2585–96.CrossRef Tashkin DP. A review of nebulized drug delivery in COPD. Int J COPD. 2016;11:2585–96.CrossRef
12.
go back to reference Ari A, Restrepo RD. Aerosol delivery device selection for spontaneously breathing patients: 2012. Respir Care. 2012;57(4):613–26. CrossRef Ari A, Restrepo RD. Aerosol delivery device selection for spontaneously breathing patients: 2012. Respir Care. 2012;57(4):613–26. CrossRef
13.
go back to reference Laube BL, Janssens HM, de Jongh FHC, et al. Chrystyn H. ERS/ISAM Task Force Report: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–31.CrossRefPubMed Laube BL, Janssens HM, de Jongh FHC, et al. Chrystyn H. ERS/ISAM Task Force Report: What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J. 2011;37:1308–31.CrossRefPubMed
14.
go back to reference Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19: Article 10.CrossRef Usmani OS, Lavorini F, Marshall J, et al. Critical inhaler errors in asthma and COPD: a systematic review of impact on health outcomes. Respir Res. 2018;19: Article 10.CrossRef
15.
go back to reference Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe. 2015;11(2):111–8.CrossRef Agent P, Parrott H. Inhaled therapy in cystic fibrosis: agents, devices and regimens. Breathe. 2015;11(2):111–8.CrossRef
16.
go back to reference Loffert D, Ikle D, Nelson H. A comparison of commercial jet nebulizers. Chest. 1994;106(6):1788–92.CrossRefPubMed Loffert D, Ikle D, Nelson H. A comparison of commercial jet nebulizers. Chest. 1994;106(6):1788–92.CrossRefPubMed
17.
go back to reference Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest. 1992;101(2):316–9.CrossRefPubMed Alvine GF, Rodgers P, Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest. 1992;101(2):316–9.CrossRefPubMed
18.
go back to reference Tenney S, Remmers J. Comparative quantitative morphology of the mammalian lung: diffusing area. Nature. 1963;197:54–6.CrossRefPubMed Tenney S, Remmers J. Comparative quantitative morphology of the mammalian lung: diffusing area. Nature. 1963;197:54–6.CrossRefPubMed
19.
20.
go back to reference Eidt-Koch D, Wagner TOF, Mittendorf F, von der Schulenberg J-M. Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy. 2010;8(2):111–8.CrossRefPubMed Eidt-Koch D, Wagner TOF, Mittendorf F, von der Schulenberg J-M. Outpatient medication costs of patients with cystic fibrosis in Germany. Appl Health Econ Health Policy. 2010;8(2):111–8.CrossRefPubMed
21.
go back to reference Flume PA, O’sullivan BP, Robinson KA, et al. Cystic fibrosis foundation, pulmonary therapies committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.CrossRefPubMed Flume PA, O’sullivan BP, Robinson KA, et al. Cystic fibrosis foundation, pulmonary therapies committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957–69.CrossRefPubMed
22.
go back to reference Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.CrossRefPubMed Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680–9.CrossRefPubMed
23.
go back to reference Pryor JA, Tannenbaum E, Scott SF. Beyond postural drainage and percussion: airway clearance in people with cystic fibrosis. J Cystic Fibrosis. 2010;9:187–92.CrossRef Pryor JA, Tannenbaum E, Scott SF. Beyond postural drainage and percussion: airway clearance in people with cystic fibrosis. J Cystic Fibrosis. 2010;9:187–92.CrossRef
24.
go back to reference Berg EB, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care. 2009;54(12):1671–8.PubMed Berg EB, Picard RJ. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respir Care. 2009;54(12):1671–8.PubMed
25.
go back to reference Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45(6):609–22.PubMed Hess DR. Nebulizers: principles and performance. Respir Care. 2000;45(6):609–22.PubMed
26.
go back to reference Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–12.CrossRefPubMedPubMedCentral Labiris NR, Dolovich MB. Pulmonary drug delivery. Part II: The role of inhalant delivery devices and drug formulations in therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):600–12.CrossRefPubMedPubMedCentral
27.
28.
go back to reference United States Pharmacopeial Convention. Chapter <1601>: Products for nebulization – Characterization tests. United States Pharmacopeia, Rockville, MD, USA. Available at: https://www.uspnf.com/. Accessed Oct 3, 2023. United States Pharmacopeial Convention. Chapter <1601>: Products for nebulization – Characterization tests. United States Pharmacopeia, Rockville, MD, USA. Available at: https://​www.​uspnf.​com/​. Accessed Oct 3, 2023.
29.
go back to reference Grasmeijer N, Frijlink HW, Hinrichs WLU. An adaptable model for growth and/or shrinkage of droplets in the respiratory tract during inhalation of aqueous particles. J Aerosol Sci. 2016;93:21–34.CrossRef Grasmeijer N, Frijlink HW, Hinrichs WLU. An adaptable model for growth and/or shrinkage of droplets in the respiratory tract during inhalation of aqueous particles. J Aerosol Sci. 2016;93:21–34.CrossRef
30.
go back to reference Eakin MN, Bilderback MS, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–64.CrossRefPubMedPubMedCentral Eakin MN, Bilderback MS, Boyle MP, Mogayzel PJ, Riekert KA. Longitudinal association between medication adherence and lung health in people with cystic fibrosis. J Cyst Fibros. 2011;10(4):258–64.CrossRefPubMedPubMedCentral
32.
go back to reference Dennis JH, Pieron CA, Pagels J, Smurthwaite M, Nerbrink O. Development and application of a low flow cascade impactor to size nebulized aerosols. J Aerosol Med. 1999;1999(12):134. Dennis JH, Pieron CA, Pagels J, Smurthwaite M, Nerbrink O. Development and application of a low flow cascade impactor to size nebulized aerosols. J Aerosol Med. 1999;1999(12):134.
Metadata
Title
Interchanging Reusable and Disposable Nebulizers Used with Home-Based Compressors May Result in Inconsistent Dosing: A Laboratory Investigation with Device Combinations Supplied to the US Healthcare Environment
Authors
Judy Schloss
Dominic P. Coppolo
Jason A. Suggett
Mark W. Nagel
Jolyon P. Mitchell
Publication date
15-04-2024
Publisher
Springer Healthcare
Published in
Pulmonary Therapy
Print ISSN: 2364-1754
Electronic ISSN: 2364-1746
DOI
https://doi.org/10.1007/s41030-024-00256-0
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.